The purpose was to see how guselkumab stacked up in terms of efficacy and safety in the 335 participants with psoriatic arthritis
versus the 1,494 without the rheumatologic disease.
The FDA approval was based on data from the Phase three Oral Psoriatic Arthritis
Trial clinical development program, which consisted of two pivotal studies, OPAL Broaden and OPAL Beyond, and available data from an ongoing long-term extension trial, OPAL Balance.
The FDA approval of XELJANZ for the treatment of adult patients with active PsA was based on data from the Phase 3 Oral Psoriatic Arthritis
Trial (OPAL) clinical development program, which consisted of two pivotal studies, OPAL Broaden and OPAL Beyond, as well as available data from an ongoing long-term extension trial, OPAL Balance.
2 Psoriatic arthritis
(PsA) is one of the complications of psoriasis.
Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis
Inflammatory arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis
(PsA) usually damages the small joints of the limbs causing severe disabilities.
Management of psoriatic arthritis
comprises the treatment of skin and joints and control of the associated comorbidity.
There have been various methods used over the years, although the standard that is currently considered the most specific is the CIASsification of Psoriatic ARthritis
(CASPAR) criteria, which require the presence of inflammation in a joint, the spine, or entheses plus at least 3 points from the following factors: presence of current psoriasis (2 points) or a personal or family history of psoriasis (1 point), dactylitis (1 point), pitting or ridging of the nails (1 point), a negative rheumatoid factor (1 point), and radiographic evidence of new bone formation (1 point).
After adjusting for traditional risk factors, the team found an excess risk for major cardiovascular events in patients with psoriatic arthritis
who were not prescribed DMARDs, in those with severe psoriasis; and in patients with RA who were or who were not prescribed DMARDs.
It also reviews key players involved in the therapeutic development for Psoriatic Arthritis
and special features on late-stage and discontinued projects.
Otezla is the first oral therapy available for the treatment of psoriatic arthritis
Celgene Corporation said the US Food and Drug Administration (FDA) has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis
(PsA) is an inflammatory disease which accompanies psoriasis which is characterized by bone proliferation, osteolysis, and involvement of the enthesis regions.
SAN DIEGO - Depression is an independent risk factor for acute myocardial infarction in patients with psoriasis or psoriatic arthritis
, a large study indicates.
In this supplement, we review the current data on the use of MTX in rheumatoid arthritis and psoriatic arthritis
, the leading inflammatory arthritic conditions where MTX is used, with articles covering the mechanisms of action of MTX, its role as the anchor drug for rheumatoid arthritis, different combinations it has been used in, its role in psoriatic arthritis
, and finally reviewing the parenteral use data in rheumatoid arthritis.